Cephalon exercises option to acquire Ception for $250 million

Cephalon offered $250 million to purchase Ception Therapeutics, exercising an exclusive option to acquire the company as part of a $100 million deal previously signed. The move comes after Cinquil, Ception's drug candidate for eosinophilic asthma, yielded positive results in a clinical trial.

View Full Article in:

American City Business Journals · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC